Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | MPL | P40238 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306356 | 0.78 | NUDT1 (0.57) | NUDT1KDM4EALDH1A1ADORA2AEGLN2 | |
| SCHEMBL3305287 | 0.76 | KDM4E (0.60) | NUDT1GRM4KDM4EALDH1A1EGLN2 | |
| SCHEMBL2256835 | 0.76 | POLB (0.42) | NUDT1GRM4KDM4EALDH1A1EGLN2 | |
| SCHEMBL13504386 | 0.76 | NUDT1 (0.62) | NUDT1KDM4EALDH1A1ADORA2AMPL | |
| SCHEMBL10855879 | 0.72 | NUDT1 (0.42) | NUDT1GRM4KDM4EALDH1A1PDE10A | |
| SCHEMBL10852850 | 0.72 | EGLN2 (0.38) | NUDT1KDM4EALDH1A1ADORA2AEGLN2 | |
| SCHEMBL10594663 | 0.72 | NUDT1 (0.41) | NUDT1KDM4EALDH1A1ADORA2AEGLN2 | |
| SCHEMBL3304584 | 0.71 | NUDT1 (0.44) | NUDT1KDM4EALDH1A1EGLN2 | |
| SCHEMBL10594458 | 0.71 | KDM4E (0.58) | NUDT1KDM4EALDH1A1CDC7 | |
| SCHEMBL10594383 | 0.71 | NUDT1 (0.48) | NUDT1KDM4EALDH1A1ADORA2AEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| US-4579848-A | ANTIASTHMA AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | NUDT1 1120/4885GRM4 2998/4885KDM4E 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.